Showing results (1-10 of 53) with videos related to

Sort By:
Pageof 6
Cardiology Journal|June 11, 2010
Percutaneous removal of endocardial implantable cardioverter-defibrillator lead displaced to the right pulmonary arteryBarbara Małecka, Andrzej Kutarski, Andrzej Zabek, et al.
Kardiologia Polska|April 11, 2017
"Buddy wire" for facilitation of femoral venous access for cryoablation: a preliminary reportAleksander Maciąg, Michał Farkowski, Jan Ciszewski, et al.
Kardiologia Polska|November 8, 2005
[Thrombus visualisation during radiofrequency catheter ablation. A case report]Aleksander Maciag, Hanna Szwed, Mariusz Pytkowski, et al.
European Heart Journal. Case Reports|December 15, 2025
Implanting a gold-coated cardioverter-defibrillator as a solution to cardiac implantable device hypersensitivity: a case reportGrzegorz Ehrenhalt, Paweł Syska, Leszek Blicharz, et al.
Polskie Archiwum Medycyny Wewnetrznej|April 1, 2004
[Successful radiofrequency catheter ablation of the symptomatic ventricular tachycardia in structurally normal heart. Case report]Aleksander Maciag, Maciej Sterliński, Mariusz Pytkowski, et al.
Kardiologia Polska|June 26, 2013
Radiofrequency ablation of numerous premature ventricular contractions in a cardiac resynchronisation therapy patient: a long-term follow-upMichał Mirosław Farkowski, Tomasz Chwyczko, Maciej Sterliński, et al.
Trials|September 13, 2012
Clinical efficacy of antazoline in rapid cardioversion of paroxysmal atrial fibrillation--a protocol of a single center, randomized, double-blind, placebo-controlled study (the AnPAF Study)Michal M Farkowski, Aleksander Maciag, Rafal Dabrowski, et al.
Cardiovascular Therapeutics|October 4, 2018
Clinical effectiveness and safety of antazoline-based therapy in patients with stable coronary artery disease undergoing pharmacological cardioversion of short-duration atrial fibrillation in the emergency departmentMichal M Farkowski, Aleksander Maciag, Malgorzata Zurawska, et al.
British Journal of Clinical Pharmacology|March 29, 2019
Intravenous antazoline, a first-generation antihistaminic drug with antiarrhythmic properties, is a suitable agent for pharmacological cardioversion of atrial fibrillation induced during pulmonary vein isolation due to the lack of influence on atrio-venous conduction and high clinical effectiveness (AntaEP Study)Michal M Farkowski, Aleksander Maciag, Ilona Kowalik, et al.
Kardiologia Polska|December 3, 2013
Translation and cultural adaptation of a Patient Perception of Arrhythmia Questionnaire in PolandMichał Mirosław Farkowski, Mariusz Pytkowski, Dominik Golicki, et al.
Pageof 6